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ABSTRACT
Background In 2010 the World Health Assembly called for action to improve the care and prevention of congenital disorders, noting that technical
guidance would be required for this task, especially in low- and middle-income countries. Responding to this call, we have developed a freely
available web-accessible Toolkit for assessing health needs for congenital disorders.
Methods Materials for the Toolkit website (http://toolkit.phgfoundation.org) were prepared by an iterative process of writing, discussion and
modification by the project team, with advice from external experts. A customized database was developed using epidemiological, demographic,
socio-economic and health-services data from a range of validated sources. Document-processing and data integration software combines data
from the database with a template to generate topic- and country-specific Calculator documents for quantitative analysis.
Results The Toolkit guides users through selection of topics (including both clinical conditions and relevant health services), assembly and
evaluation of qualitative and quantitative information, assessment of the potential effects of selected interventions, and planning and
prioritization of actions to reduce the risk or prevalence of congenital disorders.
Conclusions The Toolkit enables users without epidemiological or public health expertise to undertake health needs assessment as a prerequisite
for strategic planning in relation to congenital disorders in their country or region.
Keywords chromosomal disorders, congenital disorders, health services, population-based and preventative services
Background
Throughout the world, but particularly in low- and middle-
income countries (LMICs), the burden of congenital disorders
contributes substantially to death, disability and disadvantage
for individuals, families, communities and countries.
The terms ‘congenital disorder’ or ‘birth defect’ refer to any
abnormality affecting body structure or function that is present
from birth. Congenital disorders include chromosomal and
single-gene disorders, conditions with multifactorial inheritance
(e.g. malformations of single or multiple organs or limbs) and
disorders caused by maternal or environmental factors such as
exposure to teratogens, maternal infections and diabetes.
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A range of determinants inﬂuence the occurrence and se-
verity of congenital disorders. Risk factors include advanced
parental age, parental consanguinity, residence in or origin
from places where malaria is (or was) common, micronutrient
deﬁciencies (e.g. folate and iodine), and infection during preg-
nancy. Wider determinants of outcomes include the country’s
level of development; access to, and quality of health and
other services and the inﬂuence of cultural, religious, ethical
and legal factors.
The epidemiological transition in many LMICs has been
characterized by reductions in infant and child morbidity and
mortality, especially from infectious diseases.1 As the burden
of disease from these conditions falls, an increasing propor-
tion of the remaining morbidity and mortality in the popula-
tion is related to congenital disorders.2,3 Every year,
5 million babies are born with a severe genetic disorder or
congenital malformation, and nearly 3 million children under
the age of 5 years die from one of these conditions.1,4 This
burden is further highlighted by the recent Global Burden of
Disease (GBD) 2010 study5 update which ranked congenital
disorders as one of the leading causes of deaths and
disability-adjusted life years (DALYs) for under-5s at the
global level.
There is a widespread misconception that little can be done
about congenital disorders. On the contrary, up to 70% of
congenital disorders can be either prevented, or managed
in such a way as to considerably reduce mortality and
disability.4,6 However in LMICs, where more than 90% of
affected births occur,1 preventive and therapeutic services are
often still rudimentary.
Effective actions to reduce the burden of congenital disor-
ders have been recognized as essential for achieving the
Millennium Development Goal for child mortality.7
Signiﬁcantly, the May 2010 World Health Assembly (WHA)
passed a resolution calling on member states to ‘prevent birth
defects wherever possible, to implement screening pro-
grammes, and to provide ongoing support and care to children
with birth defects and their families’.8 The WHA resolution
noted that ‘international technical guidance will be required to
help ministries with organized assessment of requirements and
costs and with support in choosing priorities’.
The task of developing programmes to tackle congenital
disorders is challenging for many countries. Problems include
the diverse range of conditions, the paucity of reliable epi-
demiological and health-services data, and lack of expertise
and resources. Recognizing these difﬁculties, the Foundation
for Genomics and Population Health (PHG Foundation)
established the Born Healthy programme in 2009. The major
component of this programme is a freely available
web-accessible ‘Toolkit’: a step-wise guide based on the
principles of health needs assessment (HNA) as a prerequisite
for strategic planning in relation to congenital disorders.
HNA involves integration of three main sets of data:
(i) demographic and epidemiological; (ii) effectiveness of
interventions and (iii) assessment of current services, to
develop an agreed set of priorities for action. In practice the
planning process often stalls at the outset because of a per-
ceived lack of data. The Toolkit addresses this problem by
providing a framework within which users can begin to gather
data relevant to their own country, and giving them access to
country-speciﬁc demographic and epidemiological estimates
where they do not have direct evidence from their own
sources. These data are intended to provide a starting point
and to help users to make the initial case that data need to be
collected on the burden of these conditions.
We envisage that ofﬁcers at Ministries of Health, public
health professionals and geneticists will be the main users of
the Toolkit, but others such as primary care providers, health
promotion specialists, voluntary and patient organizations
may also ﬁnd it useful; the Toolkit is designed to be usable
without specialist public health or clinical knowledge.
Methods
Development of the Toolkit
The Toolkit materials were prepared by a core team of epide-
miologists, public health specialists and policy analysts from
the PHG Foundation, with data and informatics support
from the Centre for Health Informatics and Multiprofessional
Education (CHIME) at University College London (UCL).
Materials were developed by an iterative process of writing,
discussion and modiﬁcation by the project team, with advice
from external experts.
Part of the Toolkit development process included an inter-
national workshop attended by 50 invited experts from 12
countries in Europe, the Americas, Africa and Asia.
Participants included medical geneticists and other clinicians,
public health specialists and policy-makers from governments
and NGOs. The Toolkit materials were revised in the light of
the workshop participants’ suggestions.
The Toolkit website (http://toolkit.phgfoundation.org)
was developed in compliance with core web standards. The
aims were to minimize ﬁle sizes and to provide documents in
familiar and/or free software formats to minimize both the
cost to users and the IT skills needed.
Scope of the Toolkit
The Toolkit includes both ‘clinical topics’ and ‘service topics’.
Clinical topics were chosen for inclusion as examples of
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congenital conditions that have a substantial impact on public
health worldwide.
Clinical topics include the following:
† Congenital heart disease
† Congenital hypothyroidism and iodine deﬁciency
disorder
† Congenital rubella
† Congenital syphilis
† Down syndrome
† Fetal alcohol spectrum disorder
† Glucose-6-phosphate dehydrogenase deﬁciency
† Neural tube defects (NTDs)
† Orofacial clefts
† Rhesus D haemolytic disease of the newborn
† Sickle cell disease
† Thalassaemias.
The principle underlying the choice of service topics was that
the care and prevention of congenital disorders requires a
continuum of care that covers women in reproductive age and
during pregnancy and childbirth, the neonate and the devel-
oping child up to adulthood. Within this continuum, oppor-
tunities for interventions include carrier screening, family
planning, preconception care and counselling, prenatal care
and screening, obstetric services, neonatal care and screening,
and health and social care throughout childhood and adult
life.
Service topics include the following:
† Health services (capacity and organization)
† Newborn screening (including screening for inherited
metabolic disorders)
† Preconception care and screening
† Prenatal care and screening
† Teratogens (including teratogen information services).
The Toolkit is not intended to provide detailed clinical infor-
mation on diagnosis or management, but rather to guide the
process of assessing the availability and quality of existing ser-
vices and interventions and identifying areas for action and
improvement.
Toolkit data
The Toolkit provides indicative demographic, health service,
socio-economic and epidemiological data drawn from a cus-
tomized database (the PHGDB) developed by the PHG
Foundation. These data are provided as a starting point, or to
provide modelled estimates where no local data are available.
Users are encouraged to use and evaluate their own data
wherever possible.
Data in the PHGDB relate to speciﬁc countries and, in
some cases, to world regions. The PHGDB groups countries
into the same 21 geographical regions as the GBD 2010
Study.9 Demographic data for each country were compiled
from a range of resources.10–14 Particular data, such as popu-
lation data, were chosen to provide a coherent set and to
allow quick comparisons between countries and so were not
necessarily the most up-to-date data in every case.
The principal source for epidemiological data on congeni-
tal disorders was the Modell Global Database of
Constitutional Congenital Disorders (MGDB), developed by
Modell and colleagues at UCL CHIME1 with data updated
in 2011 for submission to the GBD study. The MGDB pro-
vides country-level epidemiological estimates for severe con-
genital anomalies (those classiﬁed by ICD10 codes Q00–
Q99: ‘congenital malformations, deformations and chromo-
somal abnormalities’). (Note that the MGDB does not
include data for congenital disorders caused by environmen-
tal factors such as teratogen exposure or maternal infection.)
The MGDB is constructed from data obtained by extensive
literature searches and from registries of congenital anomal-
ies, supplemented by data derived from mathematical model-
ling.1 Outcomes from the modelling process include, for
each condition and country, the potential birth prevalence
for the condition in the absence of any interventions and the
estimated actual birth prevalence based on the estimated
effects of selected preventive interventions. The incorpor-
ation of data on current and past mortality, and on the oper-
ation and coverage of health services and therapeutic
interventions, allows estimation of the number of people
living with the condition by age group, gender and degree of
severity, and of age-speciﬁc condition-speciﬁc mortality.
When country-level data from the GBD study9 and the
Child Health Epidemiology Reference Group (CHERG,
www.cherg.org) are publicly available, the Toolkit will include
reference to these data.
Document-processing and data integration software, also
developed for the Toolkit, combines relevant PHGDB data
with a template to generate topic- and country-speciﬁc
Calculator documents in multiple formats (Adobe PDF,
Microsoft Excel and Open Document Spreadsheet Formats).
Results
Conducting the HNA
The procedure for a full HNA is outlined in Fig. 1 and
described in detail in the Toolkit website (http://toolkit.
phgfoundation.org). The user ﬁrst completes the ‘Getting
Started’ document, which guides them through a structured
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approach to assembling the necessary expertise and resources,
and choosing their HNA topic(s), then navigates from the
home page to a World Health Organization (WHO) region, a
country and then their chosen topic. A ‘Supporting
Document’ provides supplementary information on parental
consanguinity; ethical, legal and social issues; patient engage-
ment; health economics; prioritization; overview of methods
used by the MGDB and a glossary.
For each topic, the main substance of the HNA is con-
tained within the HNA ‘Tool’ supported by the ‘Background’
document and the ‘Calculator’. The ‘Background’ docu-
ment provides a core knowledge base for a speciﬁc topic.
The HNA ‘Tool’ leads the user through the HNA process
and the recording of qualitative and summary information,
while the associated ‘Calculator’ enables the user to record
and compare quantitative data on epidemiological indica-
tors and to calculate the potential effects of selected inter-
ventions on the risk or prevalence of congenital disorders.
At present these interventions include folic acid fortiﬁca-
tion of food and targeted dietary folic acid supplementa-
tion, termination of pregnancy (where appropriate) and
measures to reduce risks associated with advanced maternal
age.
HNA for each clinical topic consists of seven sections:
† Country proﬁle
† Epidemiology
† Interventions
† Needs assessment
† Situation assessment
† Initial prioritization
† Summary report.
When HNA is carried out for more than one topic, the
‘Prioritization and Planning’ document enables the results of
separate HNAs to be brought together so that the user can
prioritize action areas and devise an integrated plan of action.
The ‘Final Report’ enables users to consolidate the ﬁndings
into a summary report for stakeholders.
Examples of using the Toolkit
An important strength of the Toolkit is its ﬂexibility. Not all
users may need, or have the resources, to carry out a full
HNA for a topic. They can choose, for example, just to use
the epidemiology section to collate data on the burden of
disease or to concentrate on qualitative evaluation of their
existing services. A full HNA can be completed at a later date
if resources allow.
Here we provide a few examples in which features of the
Toolkit have been used for speciﬁc purposes.
Developing a country-speciﬁc proﬁle
At a recent WHO South East Asia Regional Ofﬁce meeting,
countries were asked to put together a brief country proﬁle as
a baseline for developing a strategy for tackling congenital dis-
orders. Box 1 shows an example of a proﬁle that could have
been readily assembled from the Toolkit by an individual
without epidemiological expertise. The data, drawn from the
PHGDB, include both demographic and health-services data
(sources and year of data shown in brackets), and
Recognition of unmet need
Visit toolkit.phgfoundation.org
Preparatory resources
HNA for
topic in country
repeated for each
topic of interest
Concluding resources
Overview document
Introduction to HNA and methodology
Getting started
Guide to using the toolkit
Supporting document
Topic background
Topic tool
Topic- & country-specific calculator
Prioritisation
and planning Final report
Evidence-Based Advocacy and Service Development
Fig. 1 Schematic representation of use of the Toolkit to carry out HNA, showing possible iteration over multiple topics
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epidemiological data (sourced from the MGDB) on speciﬁc
types of congenital disorders. Together, this information,
based on well-referenced and up-to-date sources, provides an
immediate snapshot of the burden of congenital disorders in
the country and the context for developing services for care
and prevention.
Box 1 Profile for Bhutan
Bhutan is a small country with a population of 634 000 (UN
2011, data for 2005). It is situated in the Himalayan region
between India and China, and falls within the WHO South East
Asia region. The population of Bhutan is largely rural, with the
majority of the 12 000 annual births (UNICEF 2007) taking
place at home. Approximately 88% of pregnant women have
at least one prenatal visit (WHO, 2007) and 71.5% of births are
attended by a skilled health professional (WHO, 2007). Infant
mortality is 44 per 1000 births (UNICEF, 2011, data for 2010)
and average life expectancy at birth is 63 years (WHO, 2009).
There are relatively few doctors and nurses/midwives per capita
[0.2 and 3.2 per 10 000 population, respectively (WHO, 2007)],
suggesting that much of the health burden falls on the immedi-
ate and extended family.
Data from PHGDB estimate that 857 children are born with con-
genital disorders annually in Bhutan. These comprise 327 with
congenital heart disease, 220 with NTDs, 111 with orofacial
clefts, 109 with Down syndrome, 40 with rhesus D haemolytic
disease of the newborn, 34 with G6PD deficiency and 16 with
congenital hypothyroidism.
Regional comparisons
Table 1 compares epidemiological data from the Toolkit for
the birth prevalence of beta-thalassaemia and overall haemo-
globin disorders in India with data from a recent systematic
review of the literature. The generally close correspondence
conﬁrms that the Toolkit offers a reliable way of estimating
the magnitude of the burden of disease. Table 2, showing
data from the PHGDB both for India and for the wider
South Asian Region, illustrates how the Toolkit enables com-
parisons between countries and regions; such a comparative
approach can help to highlight areas of particular need.
Estimating the potential effects of interventions
The Toolkit can be used to evaluate the potential effects of
selected new interventions or of changes (for example, cover-
age) in existing interventions such as folic acid fortiﬁcation of
foods, which is known to affect the birth prevalence of
NTDs. For example, in a population with a 2/1000 birth
prevalence of NTD and where the coverage of folic acid food
fortiﬁcation at 2 ppm is 80%, the Toolkit Calculator predicts
that a change in both coverage (from 80 to 90%) and in con-
centration of folic acid in ﬂour (from 2 to 2.5 ppm) could po-
tentially reduce birth prevalence by 20% to 1.6/1000.
Figure 2, based on estimates for Egypt, shows that a reduc-
tion from 11 to 8% in the prevalence of motherhood over 35
Table 1 Epidemiological information on beta-thalassaemia and overall
haemoglobin disorders in India
India PHGDBa Sinha et al.20
Beta-thalassaemia carrier frequency 4.6% 3–4%21
No. of beta-thalassaemia carriers 49.0 million 35.1–46.8 million
Beta-thalassaemia births per year 6000b 10 000–15 00022–24
Pathological haemoglobin
disordersc births per year
32 500b 32 400
Pathological haemoglobin
disordersc birth rate
1.23/1000 1.2/10001
aModell: parental consanguinity factored in (p2 þ Fpq) þ 2(pq 2 Fpq) þ
(q2 þ Fpq) ¼ 1, where p is the frequency of variable 1, q the frequency of
variable 2 and F the population coefficient of parental consanguinity.25
bModell estimates are the most conservative that are permitted by the
data available (i.e. believed to be minimum estimates).25
cPathological haemoglobin disorders are sickle cell disease,
beta-thalassaemia, alpha zero thalassaemia and Hb H disease.
Table 2 PHGDB data for haemoglobin disorders in India and the South
Asia Region
India Sickle cell
disease in
India
Sickle cell
disease in
SAR
Beta-
thalassaemia
in India
Beta-
thalassaemia
in SAR
Live birth
prevalence/
1000
1.02 0.73 0.24 0.43
No. of affected
live births
26 451 26 805 6076 15 618
Infant
mortality rate/
1000 births
0.23 0.17 0.01 0.03
No. of infant
deaths
6104 6252 298 935
Under-5
mortality rate/
1000 births
0.29 0.21 0.1 0.23
No. of under-5
deaths
7631 7815 2683 8289
SAR, South Asia Region consisting of India, Pakistan, Afghanistan,
Bangladesh, Bhutan and Nepal.
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years of age (for example through education and/or
improved family planning services) in a country with 1.84
million births per year could lead, in the absence of any other
interventions, to a 13.4% reduction in the birth prevalence of
Down syndrome, corresponding to nearly 400 fewer affected
births per year. The relative effect will be higher, the higher
the initial proportion of births from mothers over 35 years
old. Figure 2 also illustrates the Toolkit’s approach of consid-
ering the effects of services and interventions targeting the
risk or prevalence of congenital disorders at key life stages.
Discussion
Main findings of this study
Our HNA Toolkit is a ﬂexible, user-friendly resource suitable
for users without epidemiological or public health expertise—
particularly those from LMICs—enabling them to put together
a valid and compelling case with priorities for action to reduce
the burden of congenital disease in their country or region.
What is already known on this topic
The need for action to tackle the burden of congenital disor-
ders has been recognized by the WHA, as has the require-
ment for ‘international technical guidance . . . to help
ministries with organized assessment of requirements and
costs and with support in choosing priorities’ in relation to
these conditions. The recent GBD 2010 study update further
highlighted this need, ranking congenital disorders as a
leading cause of under-5 death and DALYs at the global
level.5 HNA is a well-established approach for strategic plan-
ning of health services and thus appropriate for application in
the ﬁeld of congenital disorders.
What this study adds
The Toolkit provides a way for countries to respond to the
WHA’s call for action. A recent WHO consultation on commu-
nity genetics services in LMICs15 also recognized that epi-
demiological studies and needs assessment are an essential
prerequisite to planning and improving services for the care
and prevention of congenital disorders. The Toolkit comple-
ments the WHO’s community genetics initiative by providing a
practical, step-by-step approach for undertaking this initial task.
Needs assessment alone does not bring about improved
health services but if conducted properly it can act as a power-
ful stimulus and catalyst. From the outset, the Toolkit user is
reminded of the importance of involving—as well as the core
team who will carry out the basic work of the HNA—a broad
range of stakeholders including representation from national
(and local) Ministries of Health or equivalent institutions; the
public health services; clinical and laboratory genetics; mater-
nal and child health services; medical and health educators;
patients’ representatives, such as charities supporting those
Information from toolkit:
Effectiveness and cost-effectiveness of intervention
Local information:
Acceptability
Integration with existing services
Service development needs
Coverage
Maternal ageDeterminants
Risk education
(maternal age)Interventions
Key life
stages
Outcomes
Reproductive
age achieved Conception Live birth
Affected birth 2,885 Æ 2,49913.4% reduction
Survival with
quality of life
Number of births/yr = 1.84 million
% mothers > 35 years = 11% Æ 8%
Fig. 2 The potential impact of maternal age reduction alone on birth prevalence of Down syndrome
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with congenital disorders; expertise in ethical, legal and social
issues; expertise in health economics; professional societies
(e.g. genetics) and researchers. This inclusive approach
ensures not only that the core team has access to a broad
range of advice and expertise, but also that the full range of
those with an interest in the problem—and in particular those
who are in a position to champion change and drive it
forward—know about the initiative and support it.
To date, the Toolkit has been used by health professionals,
including medical geneticists, from three countries in South
America: Brazil, Uruguay and Argentina. Each team chose a
mix of clinical and service topics and worked through the full
HNA process, resulting in some cases in the planning and ini-
tiation of new services or interventions [for example, in Brazil
a higher prevalence at birth of NTDs has been observed due
to the lower concentration of folic acid and planning is under-
way to address this situation (Lavinia Schuler-Faccini, person-
al communication)]. The experience of the Argentinian team,
which has been published,16 was that the Toolkit was ‘action
oriented’, providing a context for building a team of stake-
holders who then had an interest in pushing forward the
agenda identiﬁed by the HNA. The team found that the
Toolkit materials were user friendly, ﬂexible and offered a sys-
tematic approach to data collection and analysis that could be
readily undertaken by those unfamiliar with the HNA
process. An additional beneﬁt was that parallel work using the
Toolkit in other countries in the region enabled the establish-
ment of a regional community of interest for those working
on the public health problem of congenital disorders. The
Argentinian team estimated that their full HNA, which
assessed policies, programmes and interventions to reduce
the burden of NTDs, required the equivalent of 3 months’
full-time work by one person.
Limitations of this study
The countries that have used the Toolkit so far have been
middle-income countries in which professional and tech-
nical resources are reasonably extensive, and basic health
services are in place. Nevertheless, even in these countries
poorly served regions or population groups were identiﬁed,
highlighting the need for improvement. Although very
poorly resourced countries may ﬁnd using the Toolkit chal-
lenging, it has been designed to enable progress to be
made from any starting point, and technical and ﬁnancial
requirements have been kept to a minimum. Recently, epi-
demiological elements of the Toolkit related to the preva-
lence of NTDs and associated risk factors have been used
in India. Feedback from lower income countries about the
utility of the Toolkit and the relevance of current and
future topics would also be valuable to identify any barriers
to uptake by this group of users.
A limitation of the research ﬁeld and therefore also of the
Toolkit is the scarcity of reliable local level epidemiological in-
formation for many countries.17–19 The mathematical model-
ling used to derive data for the Toolkit is particularly useful for
countries with no or limited data.1 Because of these uncertain-
ties in the resulting estimates, particularly for small populations,
or where there are known high rates of congenital disorders
caused by teratogen exposure or maternal infection, the use of
local data, where available, is always encouraged. It is hoped
that use of the Toolkit may act as a spur for the establishment
of new registries and research studies to collect data that will
strengthen both the HNA process and the research ﬁeld.
The Toolkit is designed to allow for updating and develop-
ment, including the production of new materials to suit needs
of speciﬁc populations. It will be particularly important that
the underlying data and evidence are kept up to date (for
example, with reference to publicly available country-level
GBD and CHERG data), a commitment that will require sig-
niﬁcant resources and leadership.
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